A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
Study of HPN424 in Patients With Advanced Prostate Cancer
Sponsor: NA
Enrolling: Male Patients Only
IRB Number: AAAR8201
U.S. Govt. ID: NCT03577028
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at treating prostate cancer. We also want to find out what effects, good and/or bad, it has on patients and their cancer. HPN424 is an intravenous drug, meaning that it is administered through a needle placed in your vein. HPN424 is intended to stimulate patient's immune systems to attack the body's prostate cancer cells. It is an experimental drug, which means it is not approved by the U.S. Food and Drug Administration to treat cancer or any other disease.
This study is closed
Mark Stein, MD
Do You Qualify?
Do you have a diagnosis of metastatic castrate-resistant prostate cancer (mCRPC)? Yes No
Have you received at least 2 prior systemic therapies approved for mCRPC? Yes No
Have you received ongoing androgen depletion therapy with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator